Baxter investment triples the company workforce in Neuchâtel
The United States pharmaceutical group, Baxter, is to create 300 more jobs at its plant in Neuchâtel over the next three years, investing a total of SFr210 million Swiss francs.
The United States pharmaceutical group, Baxter, is to create 300 more jobs at its plant in Neuchâtel over the next three years, investing a total of SFr210 million Swiss francs.
The group announced in Brussels on Wednesday that it was making total investments of SFr660 million in its Hyland Immuno division at production sites in Switzerland, Austria and California.
The Swiss site, which opened in 1995, is to manufacture a product used in the treatment of haemophilia. The plant currently has 120 employees.
Hyland Immuno produces vaccines, preparations from plasma and various drugs used in the treatment of
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
Newsletters
Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.